NCT02455557View on ClinicalTrials.gov

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 4, 2015

Primary Completion Date

October 23, 2019

Study Completion Date

November 30, 2025

Conditions
GlioblastomaGliosarcoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Montanide ISA 51 VG

Given SC

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

SVN53-67/M57-KLH Peptide Vaccine

Given SC

DRUG

Temozolomide

Given PO or IV

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Harvard Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER